vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $55.4M, roughly 1.5× PLAYSTUDIOS, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -24.7%, a 31.6% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -18.3%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $3.6M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
BLLN vs MYPS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $55.4M |
| Net Profit | $5.7M | $-13.7M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | -17.7% |
| Net Margin | 6.8% | -24.7% |
| Revenue YoY | 117.4% | -18.3% |
| Net Profit YoY | 138.3% | 38.9% |
| EPS (diluted) | $0.10 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $55.4M | ||
| Q3 25 | $83.5M | $57.6M | ||
| Q2 25 | — | $59.3M | ||
| Q1 25 | — | $62.7M | ||
| Q4 24 | — | $67.8M | ||
| Q3 24 | $38.4M | $71.2M | ||
| Q2 24 | — | $72.6M | ||
| Q1 24 | — | $77.8M |
| Q4 25 | — | $-13.7M | ||
| Q3 25 | $5.7M | $-9.1M | ||
| Q2 25 | — | $-2.9M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-22.4M | ||
| Q3 24 | $-14.9M | $-3.1M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-567.0K |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -17.7% | ||
| Q3 25 | 11.5% | -13.6% | ||
| Q2 25 | — | -5.9% | ||
| Q1 25 | — | -4.4% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | -32.9% | -6.7% | ||
| Q2 24 | — | -5.5% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | — | -24.7% | ||
| Q3 25 | 6.8% | -15.8% | ||
| Q2 25 | — | -5.0% | ||
| Q1 25 | — | -4.6% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | -38.8% | -4.3% | ||
| Q2 24 | — | -3.6% | ||
| Q1 24 | — | -0.7% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | $0.10 | $-0.07 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | $-1.47 | $-0.02 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $104.9M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $227.9M |
| Total Assets | $327.5M | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $104.9M | ||
| Q3 25 | $195.2M | $106.3M | ||
| Q2 25 | — | $112.9M | ||
| Q1 25 | — | $107.1M | ||
| Q4 24 | — | $109.2M | ||
| Q3 24 | — | $105.2M | ||
| Q2 24 | — | $106.3M | ||
| Q1 24 | — | $127.0M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $227.9M | ||
| Q3 25 | $-239.5M | $238.9M | ||
| Q2 25 | — | $245.3M | ||
| Q1 25 | — | $244.1M | ||
| Q4 24 | — | $244.7M | ||
| Q3 24 | $-242.9M | $265.2M | ||
| Q2 24 | — | $263.6M | ||
| Q1 24 | — | $288.4M |
| Q4 25 | — | $290.6M | ||
| Q3 25 | $327.5M | $299.2M | ||
| Q2 25 | — | $316.2M | ||
| Q1 25 | — | $313.8M | ||
| Q4 24 | — | $323.0M | ||
| Q3 24 | — | $330.6M | ||
| Q2 24 | — | $333.4M | ||
| Q1 24 | — | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $3.7M |
| Free Cash FlowOCF − Capex | $6.5M | $3.6M |
| FCF MarginFCF / Revenue | 7.7% | 6.5% |
| Capex IntensityCapex / Revenue | 8.8% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.7M | ||
| Q3 25 | $13.8M | $5.7M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $3.3M | ||
| Q4 24 | — | $11.6M | ||
| Q3 24 | — | $14.6M | ||
| Q2 24 | — | $14.5M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $3.6M | ||
| Q3 25 | $6.5M | $5.4M | ||
| Q2 25 | — | $13.2M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $13.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | — | $3.6M |
| Q4 25 | — | 6.5% | ||
| Q3 25 | 7.7% | 9.3% | ||
| Q2 25 | — | 22.3% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 19.6% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 4.6% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | 8.8% | 0.5% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
MYPS
Segment breakdown not available.
